Rapid identification of Coronaviruses including SARS-CoV-2 and detection of its mutations
Z-Field Technologies LCC, Los Angeles, California, United States
Diagnostic technologies for identification of SARS-CoV-2 from human nasal, buccal, or saliva samples
Tech Brief: Rapid diagnostic assay for the in-field identification of Coronaviruses including SARS-CoV-2 and detection of mutations in its spike protein from human nasal, buccal or saliva samples. It can be used by individuals without medical expertise to provide integrated sample-to-answer process flow in less than 30 minutes.
Mid-stage Startup (A or B)
FIGURES OF MERIT Value Proposition: We will provide a near-real time capability to detect Coronaviruses including SARS-CoV-2, and mutations in the spike gene. It can be used and easily read by individuals without medical expertise to provide integrated sample-to-answer process flow in less than 30 minutes. It will detect the virus and mutations in the spike protein from human nasal, buccal or saliva samples. The results can be displayed graphically and communicated to networked reporting applications. It will be easily deployed for remote use as an in-field diagnostic. The assay will be able to operate in a variety of environments for deployment at Healthcare, DoD and USG facilities worldwide. Z-Field Technologies LLC will provide value to Healthcare, DoD and USG customers by allowing them to detect the Covid-19 virus and track mutations in the spike protein of coronaviruses in near real-time with data integrated into a variety of networked reporting systems. An immediate understanding of mutations will accelerate the response times of treatment and preventative measures.